Brugada Syndrome and GPD1L: Definite Genotype-Phenotype Association?
Authors:
- Andrea GrecoAGAndrea Greco
- Estefanía Martínez-BarriosEMEstefanía Martínez-Barrios
- José CruzaleguiJCJosé Cruzalegui
- Sergi CesarSCSergi Cesar
- Fredy ChipaFCFredy Chipa
- Nuria Díez-EscutéNDNuria Díez-Escuté
- Patricia CerralboPCPatricia Cerralbo
- Irene ZschaeckIZIrene Zschaeck
- Paula LoredoPLPaula Loredo
- Georgia Sarquella-BrugadaGSGeorgia Sarquella-Brugada
- Oscar CampuzanoOscar Campuzano
Open Access
- 14 March 2025
- journal article
- review article
- Published by MDPI AG in Cardiogenetics
- Vol. 15 (1) , 9
Abstract
The GPD1L gene encodes a small cytoplasmic protein that is involved in the regulation of sodium currents. Alterations in this gene have been associated with Brugada syndrome. This rare arrhythmogenic syndrome is characterized by a typical electrocardiographic pattern, incomplete penetrance, variable expressivity, and risk of sudden cardiac death. To date, few families with a clinical diagnosis of Brugada syndrome caused by a rare alteration in the GPD1L gene have been reported worldwide. The increase in data focused on genetic variants allows us to improve the interpretation of their role in Brugada syndrome. In our study, we have compiled the GPD1L variants reported so far in patients with a definitive clinical diagnosis or suspected Brugada syndrome. We performed an exhaustive update and interpretation of each variant following the guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Our results showed that none of the variants described to date can be classified as truly harmful in Brugada syndrome. Despite this fact, more clinical and genetic data are needed to definitively rule out the GPD1L gene as a cause of Brugada syndrome. In summary, to date, there is insufficient evidence to conclude a definitive association between GPD1L and Brugada syndrome.Keywords
Funding Information
- Instituto de Salud Carlos III (PI21/00094)
- Instituto de Salud Carlos III (PI21/00094)
- European Union (PI21/00094)
- Fundació Bosch i Aymerich (PI21/00094)
- Ministry of Economy and Competitiveness of Spain (PI21/00094)
- IDIBGI (PI21/00094)
- institut de Recerca Sant joan de Deu (PI21/00094)
This publication has 34 references indexed in Scilit:
- ClinGen guidance for use of the PP1/BS4 co-segregation and PP4 phenotype specificity criteria for sequence variant pathogenicity classificationThe American Journal of Human Genetics, 2023
- Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteriaThe American Journal of Human Genetics, 2022
- Reappraisal of variants previously linked with sudden infant death syndrome: results from three population-based cohortsEuropean Journal of Human Genetics, 2019
- Genetic interpretation and clinical translation of minor genes related to Brugada syndromeHuman Mutation, 2019
- Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterionHuman Mutation, 2018
- The ACMG/AMP reputable source criteria for the interpretation of sequence variantsGenetics in Medicine, 2018
- High prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant tachycardiaHeart Rhythm, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac deathNature Genetics, 2013
- The genetic basis of Brugada syndrome: A mutation updateHuman Mutation, 2009